Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus (HCV)-encoded nonstructural protein 3 (NS3) possesses protease, NTPase, and helicase activities, which are considered essential for viral proliferation.
|
15247433 |
2004 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A missense substitution in inosine triphosphate pyrophosphatase gene affects ribavirin-induced anemia in hepatitis C virus-infected Japanese patients.
|
20637204 |
2010 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An association between a single nucleotide polymorphism (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene and reduction of hemoglobin during peg-interferon plus ribavirin combination therapy for patients with chronic hepatitis C virus (HCV) infection has been reported.
|
21503919 |
2011 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Anaemia is a common side effect of ribavirin (RBV) which is used for the treatment of hepatitis C. Inosine triphosphatase gene polymorphism (C to A) protects against RBV-induced anaemia.
|
22571903 |
2012 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Characterization and mutational analysis of the helicase and NTPase activities of hepatitis C virus full-length NS3 protein.
|
10092010 |
1999 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Forty patients infected with hepatitis C virus (HCV) genotype 1 and starting anti-HCV therapy with telaprevir in combination with pegylated-IFN/ribavirin were prospectively evaluated for SNPs at the SLC29A1 gene and inosine triphosphatase (ITPA) genes using a real-time PCR system.
|
25583751 |
2015 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic variants in the ITPA gene protected against RBV treatment-induced anemia among Caucasian patients with chronic HCV infection.
|
26441325 |
2015 |
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment of hepatitis C virus (HCV).
|
29851985 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genome-wide association studies have recently identified genetic variants, most notably IL28B and ITPA, which will enhance the ability of clinicians to personalize antiviral therapy for HCV infection.
|
21867933 |
2011 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.
|
21628662 |
2011 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.
|
22028438 |
2011 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection.
|
23195617 |
2013 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection.
|
26250055 |
2015 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In 66 patients with HCV genotype 1 who had a late viral response (LVR) to 72-week treatment of pegylated-interferon and RBV, we examined the factors that determined the outcome, including single nucleotide polymorphisms of interleukin-28B and inosine triphosphatase (ITPA) genes.
|
23980585 |
2014 |
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Individuals with lower inosine triphosphatase (ITPA) enzyme activity have a reduced likelihood of experiencing hemolytic anemia during hepatitis C virus (HCV) treatment containing ribavirin (RBV).
|
27349952 |
2017 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis showed that IPTA rs1127354 non-genotype CC, HCV genotype, a baseline HCV RNA level <4 × 10 IU/mL, IL-28B rs12979860 genotype CC, and low liver fibrosis were independent predictors for SVR during the combination therapy.IPTA rs1127354 variants and related ITPase were not only related with ribavirin-induced hemolytic anemia but also directly affected the SVR to PEG-IFN plus ribavirin combination therapy in Chinese HCV-infected patients.
|
28723780 |
2017 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polymorphisms in the inosine triphosphatase (ITPA) gene is associated with anemia induced by peg-interferon (PEG-IFN) plus ribavirin (RBV) treatment for patients with chronic hepatitis C virus (HCV) infection.
|
27822709 |
2017 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of the ITPA gene have been associated with anemia during combination therapy in hepatitis C virus (HCV)-monoinfected patients.
|
22430973 |
2012 |
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Presence of HCV RNA did not influence ITPase activity.
|
25968438 |
2015 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of IL-28B and ITPA genotypes in Chinese Han population infected persistently with hepatitis C virus genotype 6 or HCV-1.
|
23918534 |
2013 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, genome-wide association studies (GWAS) in patients with chronic hepatitis C virus (HCV) infection have identified two functional single nucleotide polymorphisms (SNPs) in the inosine triphosphatase (ITPA) gene, that are associated strongly and independently with hemolytic anemia in patients exposed to pegylated-interferon (Peg-IFN) plus ribavirin (RBV) combined therapy.
|
23201294 |
2013 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.
|
26071337 |
2015 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rs1127354 ITPA polymorphism plays a decisive role in protecting against treatment-induced anemia and the need for RBV dose reduction in Egyptian HCV patients.
|
23538996 |
2013 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The ITPA SNP rs1127354 is a useful predictor of ribavirin-induced anemia in Taiwanese patients and may be related to more severe decreases in platelet counts during the early stage of HCV combination therapy.(Gut Liver, 2015;9214-223).
|
25287171 |
2015 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The ITPA gene polymorphism rs1127354 heterozygous genotype (CA) may influence Hb levels and protect against hemolytic anemia during RBV-containing regimens for HCV.
|
28480960 |
2017 |